Search Result

Pathways Recommended:	Neuronal Signaling JAK/STAT Signaling

Results for "

IL-2 signaling

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Interleukin Related (22) Itk (1) Akt (1) Antibiotic (5) Apoptosis (5) Autophagy (5) Bacterial (5) Btk (1) Caspase (1) CD3 (1) Complement System (2) E1/E2/E3 Enzyme (2) EGFR (3) Endogenous Metabolite (2) ERK (4) FGFR (1) FKBP (5) IFNAR (6) Isotope-Labeled Compounds (1) JAK (5) MAP4K (3) p38 MAPK (2) PD-1/PD-L1 (2) Phosphatase (5) PI3K (1) Potassium Channel (2) PROTACs (1) Ras (2) Reference Standards (3) STAT (9) TNF Receptor (3) Tyrosinase (2) YAP (2)
By Research Areas:	Cancer (21) Infection (5) Inflammation/Immunology (23)

By Targets:

Interleukin Related (22)

Itk (1)

Akt (1)

Antibiotic (5)

Apoptosis (5)

Autophagy (5)

Bacterial (5)

Btk (1)

Caspase (1)

CD3 (1)

Complement System (2)

E1/E2/E3 Enzyme (2)

EGFR (3)

Endogenous Metabolite (2)

ERK (4)

FGFR (1)

FKBP (5)

IFNAR (6)

Isotope-Labeled Compounds (1)

JAK (5)

MAP4K (3)

p38 MAPK (2)

PD-1/PD-L1 (2)

Phosphatase (5)

PI3K (1)

Potassium Channel (2)

PROTACs (1)

Ras (2)

Reference Standards (3)

STAT (9)

TNF Receptor (3)

Tyrosinase (2)

YAP (2)

By Research Areas:

Cancer (21)

Infection (5)

Inflammation/Immunology (23)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: RGS Protein Itk Interleukin Related IRAK

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-13756

Tacrolimus 100+ Cited Publications FK506; Fujimycin; FR900506	Phosphatase FKBP Bacterial Autophagy Antibiotic	Infection Inflammation/Immunology Cancer
Tacrolimus (FK506), a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex. Tacrolimus inhibits calcineurin phosphatase, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties .

HY-100754

Ritlecitinib 5+ Cited Publications PF-06651600	JAK Interleukin Related STAT	Inflammation/Immunology
Ritlecitinib (PF-06651600) is a highly selective, orally active, irreversible covalent JAK3 inhibitor (IC₅₀=33 nM) without inhibitory activity towards JAK1, JAK2, and TYK2 (IC₅₀ >10 μ M). Ritlecitinib rapidly inactivates the JAK3 kinase, and blocks signaling and downstream STAT phosphorylation mediated by common gamma chain cytokines such as *IL-2* and IL-15. Ritlecitinib can inhibit Th1/Th17 cell differentiation and function, and effectively suppress preclinical animal models such as alopecia areata, adjuvant-induced arthritis (AIA), and experimental autoimmune encephalomyelitis (EAE) .

HY-126370A

Geranylgeranyl pyrophosphate triammonium	Endogenous Metabolite YAP Apoptosis Interleukin Related STAT ERK Ras	Cancer
Geranylgeranyl pyrophosphate triammonium is a type of isoprenoid metabolic intermediate, mainly synthesized through the mevalonate pathway. Geranylgeranyl pyrophosphate triammonium is a key precursor in various biological synthesis processes, especially as a necessary substrate for post-translational modification of proteins - geranylgeranyl phosphorylation. Geranylgeranyl pyrophosphate triammonium regulates various cellular processes and disease progression through protein geranylgeranyl phosphorylation, such as activating the YAP signaling pathway, promoting cell proliferation and inhibiting apoptosis; promoting *IL-2* production and STAT5 phosphorylation; and influencing metabolic homeostasis and cancer, etc .

HY-13756A

Tacrolimus monohydrate 100+ Cited Publications FK506 monohydrate; Fujimycin monohydrate; FR900506 monohydrate	Phosphatase FKBP Autophagy Bacterial Antibiotic	Infection Inflammation/Immunology Cancer
Tacrolimus monohydrate (FK506 monohydrate), a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex and inhibits calcineurin phosphatase, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties .

HY-13756S

Tacrolimus-13C,d2 1 Publications Verification FK506-¹³C,d₂; Fujimycin-¹³C,d₂; FR900506-¹³C,d₂	Phosphatase FKBP Bacterial Autophagy Antibiotic	Infection Inflammation/Immunology Cancer
Tacrolimus- ¹³C,d₂ is a ¹³C-labeled and deuterium labeled Tacrolimus. Tacrolimus (FK506), a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex. Tacrolimus inhibits calcineurin phosphatase, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties .

HY-136339

Cbl-b-IN-1 1 Publications Verification	E1/E2/E3 Enzyme Interleukin Related	Inflammation/Immunology Cancer
Cbl-b-IN-1 (Example 519) is an inhibitor of Cbl-b, with an IC₅₀ of less than 100 nM. Cbl-b-IN-1 can promote the secretion of cytokines such as IL-2, IFN-γ, and TNF-α, facilitate T cell activation, and enhance the TCR signaling pathway. Cbl-b-IN-1 can be used in research on immunomodulation .

HY-100754C

Ritlecitinib tosylate 5+ Cited Publications PF-06651600 tosylate	JAK Interleukin Related STAT	Inflammation/Immunology
Ritlecitinib (PF-06651600) tosylate is a highly selective, orally active, irreversible covalent JAK3 inhibitor (IC₅₀=33 nM) without inhibitory activity towards JAK1, JAK2, and TYK2 (IC₅₀ >10 μ M). Ritlecitinib tosylate rapidly inactivates the JAK3 kinase, and blocks signaling and downstream STAT phosphorylation mediated by common gamma chain cytokines such as *IL-2* and IL-15. Ritlecitinib tosylate can inhibit Th1/Th17 cell differentiation and function, and effectively suppress preclinical animal models such as alopecia areata, adjuvant-induced arthritis (AIA), and experimental autoimmune encephalomyelitis (EAE) .

HY-126370

Geranylgeranyl pyrophosphate	Endogenous Metabolite YAP Apoptosis Interleukin Related STAT ERK Ras	Cancer
Geranylgeranyl pyrophosphate is a type of isoprenoid metabolic intermediate, mainly synthesized through the mevalonate pathway. Geranylgeranyl pyrophosphate is a key precursor in various biological synthesis processes, especially as a necessary substrate for post-translational modification of proteins - geranylgeranyl phosphorylation. Geranylgeranyl pyrophosphate regulates various cellular processes and disease progression through protein geranylgeranyl phosphorylation, such as activating the YAP signaling pathway, promoting cell proliferation and inhibiting apoptosis; promoting *IL-2* production and STAT5 phosphorylation; and influencing metabolic homeostasis and cancer, etc .

HY-13756R

Tacrolimus (Standard) FK506 (Standard); Fujimycin (Standard); FR900506 (Standard)	Reference Standards Phosphatase FKBP Bacterial Autophagy Antibiotic	Infection Inflammation/Immunology Cancer
Tacrolimus (Standard) is the analytical standard of Tacrolimus. This product is intended for research and analytical applications. Tacrolimus (FK506), a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex. Tacrolimus inhibits calcineurin phosphatase, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties .

HY-155978A

RDN2150 TFA 1 Publications Verification	Tyrosinase ERK Interleukin Related IFNAR	Inflammation/Immunology
RDN2150 TFA is a ZAP-70 inhibitor with an IC₅₀ of 14.6 nM, and it exhibits selectivity for Syk over other kinases. RDN2150 TFA inhibits signal transduction and activation of T cells/CAR-T cells, reduces the phosphorylation level of Erk1/2, suppresses the induction of CD69 and *IL-2, and downregulates phosphotyrosine signaling* pathways including hnRNP sites in T cells. RDN2150 TFA can be used for psoriasis-related research .

HY-P991740

IBI-363	PD-1/PD-L1 Interleukin Related	Cancer
IBI-363 is a PD-1/IL-2 bispecific antibody with functions of blocking the PD-1/PD-L1 pathway and activating the IL-2 pathway. The IL-2 arm of IBI-363 retains affinity for IL-2Rα but attenuates binding ability to IL-2Rβ and IL-2Rγ to reduce toxicity. The PD-1 binding arm of IBI-363 enables PD-1 blockade and selective delivery of IL-2. IBI-363 can be used in cancer research, such as non-small cell lung cancer .

HY-P991201

REGN-7257	Interleukin Related	Inflammation/Immunology
REGN-7257 is a humanized monoclonal antibody targeting *IL2RG. REGN-7257 blocks the signal* transduction induced by common gamma chain (γc) cytokines via the *IL2RG* chain of the γc cytokine receptor complex. REGN-7257 is applicable for research on immune-mediated diseases and T cell-mediated diseases . Its corresponding isotype control is Human IgG4 kappa, Isotype Control (HY-P99003).

HY-13756S2

Tacrolimus-d3 FK506-d₃; Fujimycin-d₃; FR900506-d₃	Isotope-Labeled Compounds Autophagy FKBP Bacterial Antibiotic Phosphatase	Infection Inflammation/Immunology Cancer
Tacrolimus-d₃ (FK506-d₃) is deuterium labeled Tacrolimus. Tacrolimus (FK506), a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex. Tacrolimus inhibits calcineurin phosphatase, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties .

HY-149056

GNE-6893	MAP4K Interleukin Related	Cancer
GNE-6893 is an orally active, selective HPK1 inhibitor with a K_i < 0.02 nM. GNE-6893 enhances T cell receptor signaling in primary human T cells. GNE-6893 increases IL2 production in stimulated primary human T cells. GNE-6893 can be used for the research of chronic refractory cancers .

HY-P1453A

CMD178 TFA	STAT	Cancer
CMD178 TFA is a lead peptide that consistently reduced the expression of Foxp3 and STAT5 induced by IL-2/s IL-2Rα signaling and inhibits T_reg cell development .

HY-155978

RDN2150	Tyrosinase IFNAR ERK Interleukin Related	Inflammation/Immunology
RDN2150 is a ZAP-70 inhibitor with an IC₅₀ of 14.6 nM, and it exhibits selectivity for Syk over other kinases. RDN2150 inhibits signal transduction and activation of T cells/CAR-T cells, reduces the phosphorylation level of Erk1/2, suppresses the induction of CD69 and *IL-2, and downregulates phosphotyrosine signaling* pathways including hnRNP sites in T cells. RDN2150 can be used for psoriasis-related research .

HY-P10994

Eps8 peptide 327 Eps8(327-335)	EGFR IFNAR Interleukin Related TNF Receptor Complement System Apoptosis	Inflammation/Immunology Cancer
Eps8 peptide 327 is an HLA-A2402-restricted peptide antigen derived from Eps8 protein. Eps8 peptide 327 has potent antitumor activity with significant cytotoxicity. Eps8 peptide 327 effectively inhibits cancer cells proliferation, induces apoptosis* and disrupts EGFR signal pathway by inhibiting downstream signals (such as *IL-2, TNF-α* and IFN-γ) expression and the Eps8/EGFR interaction. Eps8 peptide 327 significantly inhibits tumor growth in HT-29 xenograft mcie models .

HY-P1409A

ADWX 1 TFA 1 Publications Verification	Potassium Channel	Inflammation/Immunology
ADWX 1 TFA is a new peptide inhibitor that is potent and selective for Kv1.3 with an IC₅₀ value of 1.89 pM. ADWX 1 inhibits Kv1.3 channel activity specifically to inhibit both the initial calcium signaling and NF-κB activation. ADWX 1 TFA ameliorates the disease in rats of experimental autoimmune encephalomyelitis (EAE) models. ADWX 1 TFA can be used to study T cell-mediated autoimmune diseases .

HY-13644

Gusperimus 15-Deoxyspergualin	Others	Others
Gusperimus is a fully synthetic racemate that has a novel mechanism of action by binding to the intracellular heat shock protein hsp70 and interfering with intracellular signal transduction. This mechanism of action can enhance the effect of immunosuppressive therapy. Gusperimus can inhibit the differentiation of T cells into cytotoxic T cells, reduce the expression of IL-2 receptors on CD4 and CD8 cells, and inhibit IFN-γ-induced B cell maturation. In addition, when used with cyclosporine, tacrolimus or mycophenolate mofetil, Gusperimus can enhance the immunosuppressive effect and prevent allogeneic transplant rejection.

HY-100754A

Ritlecitinib malonate PF-06651600 malonate	JAK Interleukin Related STAT	Inflammation/Immunology
Ritlecitinib (PF-06651600) malonate is a highly selective, orally active, irreversible covalent JAK3 inhibitor (IC₅₀=33 nM) without inhibitory activity towards JAK1, JAK2, and TYK2 (IC₅₀ >10 μ M). Ritlecitinib malonate rapidly inactivates the JAK3 kinase, and blocks signaling and downstream STAT phosphorylation mediated by common gamma chain cytokines such as *IL-2* and IL-15. Ritlecitinib malonate can inhibit Th1/Th17 cell differentiation and function, and effectively suppress preclinical animal models such as alopecia areata, adjuvant-induced arthritis (AIA), and experimental autoimmune encephalomyelitis (EAE) .

HY-168963

PROTAC BTK Degrader-13	PROTACs Btk Itk p38 MAPK	Inflammation/Immunology Cancer
PROTAC BTK Degrader-13 (Compound 25) is the PROTAC degrader for BTK with a DC₅₀ of 0.27 μM. PROTAC BTK Degrader-13 inhibits the activity of BTK with an IC₅₀ of 0.44 μM, inhibits IL-2-induced T cell kinase (ITK) with an IC₅₀ of 2.16 μM. PROTAC BTK Degrader-13 inhibits p38 MAPK signaling pathway, block the activation of the BCR (B cell receptor) signaling pathway . (Pink: ligand for target protein BTK ligand 15 (HY-168965); Black: linker (HY-Y0524); Blue: ligand for E3 ligase cereblon (HY-103596))

HY-145675A

(R)-TCB2	Interleukin Related	Inflammation/Immunology
(R)-TCB2 is the R-enantiomer of TCB2. TCB2 is a potent anti-human interleukin-2 antibody, facilitates heterodimeric IL-2 receptor signaling and improves anti-tumor immunity .

HY-173311

Cbl-b-IN-28	E1/E2/E3 Enzyme Interleukin Related	Inflammation/Immunology Cancer
Cbl-b-IN-28 (Compound B2) is an orally active Cbl-b inhibitor. Cbl-b-IN-28 promotes the secretion of cytokines such as *IL-2* and enhances the function of immune cells by regulating the phosphorylation levels of key proteins in the T-cell receptor signaling pathway. Cbl-b-IN-28 can be used in research in the field of cancer immunology .

HY-P10995

TAT-327	EGFR IFNAR Interleukin Related TNF Receptor Complement System Apoptosis	Inflammation/Immunology Cancer
TAT-327 is cell-penetrating peptide. TAT-327 selectively inserts into cancer cell membranes and shows potent antitumor activity. TAT-327 effectively inhibits cancer cells proliferation, induces apoptosis and disrupts EGFR signal pathway by inhibiting downstream signals (such as *IL-2, TNF-α* and IFN-γ) expression and the Eps8/EGFR interaction. TAT-327 significantly inhibits tumor growth in HT-29 xenograft mcie models .

HY-P5870

KTX-Sp2	Potassium Channel	Inflammation/Immunology
KTX-Sp2 is a potassium channel toxin. KTX-Sp2 effectively blocks three types of exogenous voltage-gated potassium channels: Kv1.1, Kv1.2 and Kv1.3. Ktx-Sp2 inhibits endogenous Kv1.3 and suppresses Ca ²⁺ signaling in Jurkat T cells. Ktx-Sp2 inhibits IL-2 secretion from activated Jurkat T cells .

HY-P1453

CMD178	STAT	Cancer
CMD178 is a lead peptide that consistently reduced the expression of Foxp3 and STAT5 induced by IL-2/s IL-2Rα signaling and inhibits T_reg cell development .

HY-182238

HPK1-IN-69	MAP4K Interleukin Related	Cancer
HPK1-IN-69 is an orally active HPK1 inhibitor with an IC₅₀ of 1.7 nM. HPK1-IN-69 inhibits the HPK1-mediated TCR signaling pathway, reduces the phosphorylation level of SLP76, and promotes the release of *IL-2*. HPK1-IN-69 exhibits in vivo anti-tumor activity in mouse models. HPK1-IN-69 can be used for the research of colorectal cancer and MC38 syngeneic tumors .

HY-P992161

REGN-10597	Interleukin Related PD-1/PD-L1	Inflammation/Immunology Cancer
REGN-10597, composed of an anti-huPD-1-targeting antibody and IL2Ra-IL2 moiety, is a PD-1-dependent *IL-2* agonist. REGN-10597 binds PD-1 to deliver masked native IL-2 to PD-1⁺ T cells, engaging trimeric IL-2 receptors to activate downstream signaling. REGN-10597 can be used for the research on melanoma, prostate cancer, colorectal cancer, and ovarian cancer .

HY-P991999

OM-RCA-01	FGFR IFNAR Interleukin Related	Cancer
OM-RCA-01 is an anti-FGFR1 monoclonal antibody with a K_d of 1.59 nM for human FGFR1. OM-RCA-01 inhibits the phosphorylation of FGFR1, blocks FGF-mediated signaling pathways, and suppresses the proliferation of downstream tumor cells. OM-RCA-01 delays tumor growth in lung cancer and renal cancer xenograft models expressing FGFR1. When combined with Nivolumab, OM-RCA-01 enhances the release of IFN-γ and *IL-2*. OM-RCA-01 is applicable for the research of lung cancer and renal cell carcinoma .

HY-100754R

Ritlecitinib (Standard) PF-06651600 (Standard)	JAK Reference Standards Interleukin Related STAT	Inflammation/Immunology
Ritlecitinib (Standard) is the analytical standard of Ritlecitinib (HY-100754). This product is intended for research and analytical applications. Ritlecitinib (PF-06651600) is a highly selective, orally active, irreversible covalent JAK3 inhibitor (IC50=33 nM) without inhibitory activity towards JAK1, JAK2, and TYK2 (IC50 >10 μ M). Ritlecitinib rapidly inactivates the JAK3 kinase, and blocks signaling and downstream STAT phosphorylation mediated by common gamma chain cytokines such as IL-2 and IL-15. Ritlecitinib can inhibit Th1/Th17 cell differentiation and function, and effectively suppress preclinical animal models such as alopecia areata, adjuvant-induced arthritis (AIA), and experimental autoimmune encephalomyelitis (EAE) .

HY-100754CR

Ritlecitinib tosylate (Standard) PF-06651600 tosylate (Standard)	JAK Reference Standards Interleukin Related STAT	Inflammation/Immunology
Ritlecitinib (tosylate) (Standard) is the analytical standard of Ritlecitinib (tosylate) (HY-100754C). This product is intended for research and analytical applications. Ritlecitinib (PF-06651600) tosylate is a highly selective, orally active, irreversible covalent JAK3 inhibitor (IC50=33 nM) without inhibitory activity towards JAK1, JAK2, and TYK2 (IC50 >10 μ M). Ritlecitinib tosylate rapidly inactivates the JAK3 kinase, and blocks signaling and downstream STAT phosphorylation mediated by common gamma chain cytokines such as IL-2 and IL-15. Ritlecitinib tosylate can inhibit Th1/Th17 cell differentiation and function, and effectively suppress preclinical animal models such as alopecia areata, adjuvant-induced arthritis (AIA), and experimental autoimmune encephalomyelitis (EAE) .

HY-181924

HPK1-IN-68	MAP4K Interleukin Related	Inflammation/Immunology Cancer
HPK1-IN-68 (Compound 39) is a HPK1 inhibitor with an IC₅₀ of 2.8 nM. HPK1-IN-68 blocks HPK1 signaling, inhibits HPK1-mediated phosphorylation of SLP76, and promotes the production of the *IL-2* cytokine. HPK1-IN-68 antagonizes the immunosuppressive effect mediated by PGE2. HPK1-IN-68 enhances the infiltration of CD3 ⁺/CD8 ⁺ T cells into tumor tissues. HPK1-IN-68 exerts T cell-dependent antitumor efficacy in a mouse colon cancer model. HPK1-IN-68 exhibits significant synergistic antitumor effects when used in combination with anti-PD-1. HPK1-IN-68 is applicable to research related to colon cancer .

HY-P992401

M802	EGFR CD3 PI3K Akt p38 MAPK Caspase Apoptosis IFNAR TNF Receptor Interleukin Related	Cancer
M802 is an anti-HER2/CD3 bispecific antibody, with a K_d of 0.578 nM for human HER2 and a K_d of 71.2 nM for human CD3. M802 inhibits the PI3K/AKT and MAPK signaling pathways, suppresses tumor cell proliferation, activates caspase-3, and promotes tumor cell apoptosis (apoptosis). M802 recruits and activates CD3-positive immune cells, mediates cytotoxicity against HER2-positive tumor cells, and induces immune cells to secrete IFN-γ, TNF-α, *IL-2* and IL-6. M802 exhibits anti-tumor efficacy in mice with gastric cancer xenografts. M802 can be used in research related to HER2-positive breast cancer, HER2-positive gastric cancer and other cancers. The recommended isotype control is human IgG1 kappa (HY-P99001) .

Cat. No.	상품명	Target	Research Area